Phase 2 STEMI Clinical Trials
99 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 99 trials
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 1Phase 2
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 2
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Digital Ulcers in Systemic Sclerosis
Topadur Pharma AG15 enrolled6 locationsNCT06954597
Recruiting
Phase 2
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled139 locationsNCT07409181
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 1Phase 2
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
Systemic Inflammatory Response SyndromeSARS CoV-2Respiratory distress syndrome+2 more
PEACHES BIOTECH50 enrolled3 locationsNCT06684379
Recruiting
Phase 2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled128 locationsNCT06470048
Recruiting
Phase 2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics85 enrolled6 locationsNCT07287670
Recruiting
Phase 1Phase 2
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
National Heart, Lung, and Blood Institute (NHLBI)78 enrolled1 locationNCT06032923
Recruiting
Phase 2
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Eisai Co., Ltd.256 enrolled22 locationsNCT07515014
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Nkarta, Inc.240 enrolled17 locationsNCT06733935
Recruiting
Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled101 locationsNCT06581198
Recruiting
Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled95 locationsNCT07015983
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
DualityBio Inc.148 enrolled7 locationsNCT06625671
Recruiting
Phase 2
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Systemic Lupus ErythematosusLupusLupus Nephritis
Hoffmann-La Roche30 enrolled15 locationsNCT07598396
Recruiting
Phase 2
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled52 locationsNCT06991114
Recruiting
Phase 2Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis
Blueprint Medicines Corporation534 enrolled68 locationsNCT04910685
Recruiting
Phase 2
2-HOBA in Systemic Lupus Erythematosus
Systemic Lupus Erthematosus (SLE)
Vanderbilt University Medical Center42 enrolled1 locationNCT07225543
Recruiting
Phase 1Phase 2
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies (Shanghai) Co., Ltd.118 enrolled2 locationsNCT06530849
Recruiting
Phase 1Phase 2
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777